Abstract GS3-00: First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPonder)-Reference-Cited by-同舟云学术

Abstract GS3-00: First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPonder)

Published:2021-02-15 Issue: Volume: Page:
ISSN:
Container-title:General Session Abstracts
language:
Short-container-title:

Author:

Kalinsky Kevin,Barlow William E,Meric-Bernstam Funda,Gralow Julie R,Albain Kathy S,Hayes Daniel,Lin Nancy,Perez Edith A,Goldstein Lori J,Chia Stephen,Dhesy-Thind Subkhbinder,Rastogi Priya,Alba Emilio,Delaloge Suzette,Martín Miguel,Gil Miguel Gil,Arce-Salinas Claudia,Brain Etienne,Park In Hae,Pierga Jean-Yves,Lluch Ana Hernandez,Vasquez Manuel Ramos,Borrego Manuel Ruiz,Jung Kyung Hae,Ferrero Jean-Marc,Schott Anne,Shak Steve,Sharma Priyanka,Lew Danika L,Miao Jieling,Tripathy Debu,Hortobagyi Gabriel,Pusztai Lajos

Publisher

American Association for Cancer Research

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Practical tools to facilitate the choice of adjuvant systemic therapy for resectable luminal HER2‑negative breast cancer;Malignant tumours;2024-05-15

2. Impact of reactive changes on multigene testing: histopathologic analysis of low-grade breast cancers with high-risk 21-gene recurrence scores;Breast Cancer Research and Treatment;2023-09-28

3. Biomarkers in Breast Cancer: An Old Story with a New End;Genes;2023-06-28

4. The Effects of the COVID-19 Pandemic on Mastectomy Outcomes for Breast Cancer;Clinical Breast Cancer;2023-06

5. Prognostic and predictive impact of gene expression in node‐positive early breast cancer patients receiving dose‐dense versus standard‐dose adjuvant chemotherapy;Molecular Oncology;2023-04-24